Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Fruquintinib, sold under the brand name Fruzaqla, is an anti-cancer medication used for the treatment of colorectal cancer. Fruquintinib is a kinase inhibitor. It is taken by mouth.
Read the full article on WikipediaMetastatic colorectal cancer Clinical criteria: Treatment Phase: Initial PBS-subsidised treatment Patient must have/had a WHO performance status of 1 or less, prior to initiation of treatment with this drug for this condition, AND Patient must not have previously received PBS-subsidised treatment with this drug for this PBS indication; OR Patient must be each of: (i) currently receiving non-PBS subsidised supply for this drug for this PBS indication, (ii) untreated with this drug at the time that non-PBS-subsidised supply was commenced, (iii) free of disease progression since commencing non-PBS-subsidised supply, AND Patient must have been previously treated with or not considered a candidate for treatment with fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapies, an anti-vascular endothelial growth factor (anti-VEGF) agent and an anti-epidermal growth factor receptor (anti-EGFR) agent for this condition, AND The treatment must be the sole PBS-subsidised therapy for this condition. The patient's WHO performance status must be documented in the patient's medical records at the time the treatment is initiated.
“42hr”
Working under the parallel aged-care framework? Aged-care equivalent →